{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:59:22Z","timestamp":1792483162773,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["2 K24-AR053120-06"],"award-info":[{"award-number":["2 K24-AR053120-06"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00198-017-4175-0","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T16:43:38Z","timestamp":1501692218000},"page":"3289-3300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"given":"T.","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Sterbenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Malay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"MacEachern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. C.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"key":"4175_CR1","volume-title":"In: bone health and osteoporosis: a report of the surgeon general","author":"(US) OotSG","year":"2004","unstructured":"(US) OotSG (2004) In: bone health and osteoporosis: a report of the surgeon general. Reports of the Surgeon General, Rockville"},{"key":"4175_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. doi:\n                    10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"key":"4175_CR3","doi-asserted-by":"crossref","unstructured":"Nih Consensus Development Panel on Osteoporosis Prevention D, Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785\u2013795","DOI":"10.1001\/jama.285.6.785"},{"issue":"1A","key":"4175_CR4","doi-asserted-by":"publisher","first-page":"35S","DOI":"10.1016\/S0002-9343(97)00415-4","volume":"102","author":"CL Deal","year":"1997","unstructured":"Deal CL (1997) Osteoporosis: prevention, diagnosis, and management. Am J Med 102(1A):35S\u201339S","journal-title":"Am J Med"},{"issue":"7","key":"4175_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s001980070075","volume":"11","author":"JA Cauley","year":"2000","unstructured":"Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11(7):556\u2013561. doi:\n                    10.1007\/s001980070075","journal-title":"Osteoporos Int"},{"issue":"4","key":"4175_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jama.297.4.387","volume":"297","author":"JR Center","year":"2007","unstructured":"Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297(4):387\u2013394. doi:\n                    10.1001\/jama.297.4.387","journal-title":"JAMA"},{"issue":"3","key":"4175_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00198-003-1514-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15(3):175\u2013179. doi:\n                    10.1007\/s00198-003-1514-0","journal-title":"Osteoporos Int"},{"issue":"18","key":"4175_CR8","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799\u20131809. doi:\n                    10.1056\/NEJMoa074941","journal-title":"N Engl J Med"},{"issue":"3","key":"4175_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res Off J Am Soc Bone Miner Res 22(3):465\u2013475. doi:\n                    10.1359\/jbmr.061113","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"4","key":"4175_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Osteoporosis Methodology G, The Osteoporosis Research Advisory G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570\u2013578","journal-title":"Endocr Rev"},{"issue":"9","key":"4175_CR11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032\u20131045. doi:\n                    10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"4175_CR12","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333(22):1437\u20131443","journal-title":"N Engl J Med"},{"issue":"24","key":"4175_CR13","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077\u20132082","journal-title":"JAMA"},{"issue":"18","key":"4175_CR14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, Trial HPF (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809\u20131822","journal-title":"N Engl J Med"},{"issue":"1","key":"4175_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1185\/03007990903427082","volume":"26","author":"A Sontag","year":"2010","unstructured":"Sontag A, Wan X, Krege JH (2010) Benefits and risks of raloxifene by vertebral fracture status. Curr Med Res Opin 26(1):71\u201376. doi:\n                    10.1185\/03007990903427082","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"4175_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. [Erratum appears in N Engl J Med 2009 Nov 5;361(19):1914]. N Engl J Med 361(8):756\u2013765. doi:\n                    10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"9077","key":"4175_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","volume":"350","author":"R Lindsay","year":"1997","unstructured":"Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350(9077):550\u2013555. doi:\n                    10.1016\/S0140-6736(97)02342-8","journal-title":"Lancet"},{"issue":"11","key":"4175_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2165\/00019053-200725110-00003","volume":"25","author":"RL Fleurence","year":"2007","unstructured":"Fleurence RL, Iglesias CP, Johnson JM (2007) The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. PharmacoEconomics 25(11):913\u2013933","journal-title":"PharmacoEconomics"},{"issue":"7","key":"4175_CR19","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.2106\/JBJS.L.01781","volume":"96","author":"A Balasubramanian","year":"2014","unstructured":"Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O'Malley CD (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96(7):e52. doi:\n                    10.2106\/JBJS.L.01781","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"4175_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00198-004-1698-y","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Barton IP, Johnell O (2005) Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 16(5):475\u2013482","journal-title":"Osteoporos Int"},{"issue":"9041","key":"4175_CR21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535\u20131541","journal-title":"Lancet"},{"issue":"1","key":"4175_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/BF01623461","volume":"7","author":"ML Montessori","year":"1997","unstructured":"Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K (1997) The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporos Int 7(1):52\u201358","journal-title":"Osteoporos Int"},{"issue":"6","key":"4175_CR23","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3109\/13697137.2015.1045484","volume":"18","author":"S Palacios","year":"2015","unstructured":"Palacios S, Kalouche-Khalil L, Rizzoli R, Zapalowski C, Resch H, Adachi JD, Gallagher JC, Feldman RG, Kendler DL, Wang A, Wagman RB, Adami S (2015) Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric 18(6):805\u2013812. doi:\n                    10.3109\/13697137.2015.1045484","journal-title":"Climacteric"},{"issue":"10","key":"4175_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006\u20131012. doi:\n                    10.1016\/j.jclinepi.2009.06.005","journal-title":"J Clin Epidemiol"},{"key":"4175_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions. Cochrane book series","author":"JPT Higgins","year":"2008","unstructured":"Higgins JPT, Green S, Cochrane Collaboration (2008) Cochrane handbook for systematic reviews of interventions. Cochrane book series. Wiley-Blackwell, Chichester"},{"issue":"4","key":"4175_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/jcem-66-4-747","volume":"66","author":"R Pacifici","year":"1988","unstructured":"Pacifici R, McMurtry C, Vered I, Rupich R, Avioli LV (1988) Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab 66(4):747\u2013753. doi:\n                    10.1210\/jcem-66-4-747","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"4175_CR27","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","volume":"322","author":"T Storm","year":"1990","unstructured":"Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322(18):1265\u20131271","journal-title":"N Engl J Med"},{"issue":"2","key":"4175_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199007123230201","volume":"323","author":"NB Watts","year":"1990","unstructured":"Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323(2):73\u201379","journal-title":"N Engl J Med"},{"issue":"6","key":"4175_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","volume":"95","author":"ST Harris","year":"1993","unstructured":"Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH 3rd (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95(6):557\u2013567","journal-title":"Am J Med"},{"issue":"6","key":"4175_CR30","first-page":"1595","volume":"79","author":"IR Reid","year":"1994","unstructured":"Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J (1994) Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79(6):1595\u20131599","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4175_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/PL00004152","volume":"7","author":"B Clemmesen","year":"1997","unstructured":"Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7(5):488\u2013495","journal-title":"Osteoporos Int"},{"issue":"4","key":"4175_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF02242451","volume":"16","author":"GP Lyritis","year":"1997","unstructured":"Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C (1997) The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clin Rheumatol 16(4):354\u2013360","journal-title":"Clin Rheumatol"},{"issue":"3","key":"4175_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","volume":"104","author":"SJ Wimalawansa","year":"1998","unstructured":"Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104(3):219\u2013226","journal-title":"Am J Med"},{"issue":"4","key":"4175_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","volume":"109","author":"CH Chesnut 3rd","year":"2000","unstructured":"Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109(4):267\u2013276","journal-title":"Am J Med"},{"issue":"1","key":"4175_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83\u201391","journal-title":"Osteoporos Int"},{"issue":"5","key":"4175_CR36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333\u2013340. doi:\n                    10.1056\/NEJM200102013440503","journal-title":"N Engl J Med"},{"issue":"19","key":"4175_CR37","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441. doi:\n                    10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"issue":"6","key":"4175_CR38","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","volume":"17","author":"C Brumsen","year":"2002","unstructured":"Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EK, Roos JC, Valentijn RM, Zwinderman AH (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17(6):1057\u20131064","journal-title":"J Bone Miner Res"},{"issue":"4","key":"4175_CR39","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","volume":"33","author":"PD Delmas","year":"2003","unstructured":"Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33(4):522\u2013532","journal-title":"Bone"},{"issue":"3","key":"4175_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4065\/80.3.343","volume":"80","author":"SA Quandt","year":"2005","unstructured":"Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM, Fracture Intervention Trial Research G (2005) Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to \u22122.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 80(3):343\u2013349","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"4175_CR41","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study G (2007) Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. [Summary for patients in Ann Intern Med. 2007 Mar 6;146(5):I20; PMID: 17339614]. Ann Intern Med 146(5):326\u2013339","journal-title":"Ann Intern Med"},{"issue":"12","key":"4175_CR42","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23(12):1923\u20131934. doi:\n                    10.1359\/jbmr.080710","journal-title":"J Bone Miner Res"},{"issue":"3","key":"4175_CR43","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00198-010-1411-2","volume":"22","author":"LA Beaupre","year":"2011","unstructured":"Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22(3):983\u2013991. doi:\n                    10.1007\/s00198-010-1411-2","journal-title":"Osteoporos Int"},{"issue":"4","key":"4175_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00774-013-0505-2","volume":"32","author":"T Nakano","year":"2014","unstructured":"Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2014) Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. J Bone Miner Metab 32(4):441\u2013446. doi:\n                    10.1007\/s00774-013-0505-2","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"4175_CR45","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2106\/JBJS.G.01121","volume":"90","author":"TD Rozental","year":"2008","unstructured":"Rozental TD, Makhni EC, Day CS, Bouxsein ML (2008) Improving evaluation and treatment for osteoporosis following distal radial fractures. A prospective randomized intervention. J Bone Joint Surg Am 90(5):953\u2013961. doi:\n                    10.2106\/JBJS.G.01121","journal-title":"J Bone Joint Surg Am"},{"issue":"11","key":"4175_CR46","first-page":"1426","volume":"166","author":"AB Hodsman","year":"2002","unstructured":"Hodsman AB, Hanley DA, Josse R (2002) Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ Can Med Assoc J 166(11):1426\u20131430","journal-title":"CMAJ Can Med Assoc J"},{"issue":"5","key":"4175_CR47","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","volume":"28","author":"NCW Harvey","year":"2017","unstructured":"Harvey NCW, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28(5):1507\u20131529. doi:\n                    10.1007\/s00198-016-3894-y","journal-title":"Osteoporos Int"},{"issue":"1-2","key":"4175_CR48","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11657-013-0126-3","volume":"8","author":"L Hansen","year":"2013","unstructured":"Hansen L, Mathiesen AS, Vestergaard P, Ehlers LH, Petersen KD (2013) A health economic analysis of osteoporotic fractures: who carries the burden? Arch Osteoporos 8(1-2):126. doi:\n                    10.1007\/S11657-013-0126-3","journal-title":"Arch Osteoporos"},{"issue":"4","key":"4175_CR49","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570\u2013578. doi:\n                    10.1210\/er.2001-9002","journal-title":"Endocr Rev"},{"key":"4175_CR50","doi-asserted-by":"publisher","first-page":"Cd004523","DOI":"10.1002\/14651858.Cd004523.Pub3","volume":"1","author":"G Wells","year":"2008","unstructured":"Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Db Syst Rev 1:Cd004523. doi:\n                    10.1002\/14651858.Cd004523.Pub3","journal-title":"Cochrane Db Syst Rev"},{"key":"4175_CR51","doi-asserted-by":"publisher","first-page":"Cd001155","DOI":"10.1002\/14651858.Cd001155.Pub2","volume":"1","author":"GA Wells","year":"2008","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Db Syst Rev 1:Cd001155. doi:\n                    10.1002\/14651858.Cd001155.Pub2","journal-title":"Cochrane Db Syst Rev"},{"key":"4175_CR52","doi-asserted-by":"publisher","first-page":"Cd003376","DOI":"10.1002\/14651858.Cd003376.Pub3","volume":"1","author":"GA Wells","year":"2008","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Db Syst Rev 1:Cd003376. doi:\n                    10.1002\/14651858.Cd003376.Pub3","journal-title":"Cochrane Db Syst Rev"},{"issue":"2","key":"4175_CR53","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1359\/jbmr.090731","volume":"25","author":"P Aspenberg","year":"2010","unstructured":"Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, Garcia-Hernandez PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC (2010) Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25(2):404\u2013414. doi:\n                    10.1359\/jbmr.090731","journal-title":"J Bone Miner Res"},{"issue":"17","key":"4175_CR54","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2106\/JBJS.J.01379","volume":"93","author":"P Peichl","year":"2011","unstructured":"Peichl P, Holzer LA, Maier R, Holzer G (2011) Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93(17):1583\u20131587. doi:\n                    10.2106\/JBJS.J.01379","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"4175_CR55","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/jbmr.3067","volume":"32","author":"J Malouf-Sierra","year":"2017","unstructured":"Malouf-Sierra J, Tarantino U, Garcia-Hernandez PA, Corradini C, Overgaard S, Stepan JJ, Borris L, Lespessailles E, Frihagen F, Papavasiliou K, Petto H, Aspenberg P, Caeiro JR, Marin F (2017) Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res 32(5):1040\u20131051. doi:\n                    10.1002\/jbmr.3067","journal-title":"J Bone Miner Res"},{"issue":"19","key":"4175_CR56","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2106\/JBJS.N.01275","volume":"97","author":"HS Bawa","year":"2015","unstructured":"Bawa HS, Weick J, Dirschl DR (2015) Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. J Bone Joint Surg Am 97(19):1555\u20131562. doi:\n                    10.2106\/JBJS.N.01275","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"4175_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00774-012-0349-1","volume":"30","author":"CA Inderjeeth","year":"2012","unstructured":"Inderjeeth CA, Chan K, Kwan K, Lai M (2012) Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab 30(5):493\u2013503. doi:\n                    10.1007\/s00774-012-0349-1","journal-title":"J Bone Miner Metab"},{"issue":"9","key":"4175_CR58","first-page":"605","volume":"14","author":"AN Tosteson","year":"2008","unstructured":"Tosteson AN, Burge RT, Marshall DA, Lindsay R (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 14(9):605\u2013615","journal-title":"Am J Manag Care"},{"issue":"2","key":"4175_CR59","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.smj.0000202090.30647.61","volume":"99","author":"AK Pfister","year":"2006","unstructured":"Pfister AK, Welch CA, Lester MD, Emmett MK, Saville PD, Duerring SA (2006) Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 99(2):123\u2013131. doi:\n                    10.1097\/01.smj.0000202090.30647.61","journal-title":"South Med J"},{"issue":"4","key":"4175_CR60","doi-asserted-by":"publisher","first-page":"A38","DOI":"10.1016\/j.jval.2012.03.215","volume":"15","author":"A Parthan","year":"2012","unstructured":"Parthan A, Deflin MM, Yurgin N, Huang J, Taylor DC (2012) Cost-effectiveness of denosumab versus oral bisphosphonates in the United States for post-menopausal osteoporosis (Pmo). Value Health 15(4):A38\u2013A38","journal-title":"Value Health"},{"issue":"1","key":"4175_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11914-012-0130-3","volume":"11","author":"PJ Mitchell","year":"2013","unstructured":"Mitchell PJ (2013) Best practices in secondary fracture prevention: fracture liaison services. Current 11(1):52\u201360. doi:\n                    10.1007\/s11914-012-0130-3","journal-title":"Current"},{"issue":"6","key":"4175_CR62","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.berh.2005.07.001","volume":"19","author":"SJ Gallacher","year":"2005","unstructured":"Gallacher SJ (2005) Setting up an osteoporosis fracture liaison service: background and potential outcomes. Best Pract Res Clin Rheumatol 19(6):1081\u20131094. doi:\n                    10.1016\/j.berh.2005.07.001","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"4175_CR63","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00198-015-3443-0","volume":"27","author":"A Nakayama","year":"2016","unstructured":"Nakayama A, Major G, Holliday E, Attia J, Bogduk N (2016) Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int 27(3):873\u2013879. doi:\n                    10.1007\/s00198-015-3443-0","journal-title":"Osteoporos Int"},{"issue":"7","key":"4175_CR64","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00198-011-1642-x","volume":"22","author":"D Marsh","year":"2011","unstructured":"Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, McLellan AR, Mitchell PJ, Sale JEM, Wahl DA, Grp ICFW (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22(7):2051\u20132065. doi:\n                    10.1007\/s00198-011-1642-x","journal-title":"Osteoporos Int"},{"issue":"10","key":"4175_CR65","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/jbmr.1698","volume":"27","author":"JA Eisman","year":"2012","unstructured":"Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E, Fractur ATFS (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039\u20132046. doi:\n                    10.1002\/jbmr.1698","journal-title":"J Bone Miner Res"},{"issue":"8","key":"4175_CR66","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s00198-013-2348-z","volume":"24","author":"K Akesson","year":"2013","unstructured":"Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C (2013) Capture the fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24(8):2135\u20132152. doi:\n                    10.1007\/s00198-013-2348-z","journal-title":"Osteoporos Int"},{"issue":"3","key":"4175_CR67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","volume":"148","author":"C MacLean","year":"2008","unstructured":"MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148(3):197\u2013213","journal-title":"Ann Intern Med"},{"key":"4175_CR68","doi-asserted-by":"publisher","first-page":"nihpa40967","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:nihpa40967. doi:\n                    10.1056\/NEJMoa074941","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-4175-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T07:41:11Z","timestamp":1589442071000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-4175-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4175-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,2]]},"assertion":[{"value":"17 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}